Health
Health News
DRONE DELIVERY CANADA RECEIVES APPROVAL FOR BVLOS FLIGHTS AND DANGEROUS GOODS TRANSPORTATION ON ITS DRONECARE COMMERICAL PROJECT
TORONTO, Jan. 9, 2024 /CNW/ - Drone Delivery Canada Corp. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: A3DP5Y) or (Frankfurt: ABBA.F) (the "Company"...
Read morePanGenomic Health Signs Letter of Intent with Crescita Capital for $5 Million Equity Drawdown Facility
VANCOUVER, BC, Jan. 9, 2024 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased...
Read moreEupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf Prospectus
VICTORIA, BC, Jan. 8, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) today announced that it has...
Read moreMedison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous...
Read moreCRAFT 1861 GLOBAL AND NANO CURES INTERNATIONAL ANNOUNCE MUTUAL CONTINUATION EXTENSION OF THE ARRANGEMENT AGREEMENT COMPLETION & EFFECTIVE DATE
ALBUQUERQUE, N.M., Jan. 8, 2024 /CNW/ - CRAFT 1861 Global Holdings Inc. (Cboe Canada/NEO: HUMN), (Cboe Canada/NEO: HUMN.WT.A) (the "Company" or...
Read moreClarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report
Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent...
Read moreHain Celestial Rings NASDAQ Closing Bell
Celebrating 30 Years as a Leader of Better-For-You Brands HOBOKEN, N.J., Jan. 5, 2024 /CNW/ -- The Hain Celestial Group, Inc. (Nasdaq:...
Read moreALK deviendra l’unique fabricant et distributeur du test cutané par antigène pour le diagnostic de l’allergie à la pénicilline
- PRE-PENMD (benzyl-pénicilloyl polylysine injectable, USP) est le seul test de diagnostic cutané approuvé par la FDA pour évaluer l'allergie...
Read moreFusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates
Aligned with the FDA on submitted protocol for 225Ac-PSMA (FPI-2265) Phase 2/3 registrational program for patients with metastatic castration-resistant prostate...
Read moreOncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
SAN DIEGO, CA and CALGARY, AB, Jan. 4, 2024 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused...
Read more